[Previous] Blurberati Blog » What's Your Color IQ?...

 [Next] Nitto Denko and Quark Pharmaceuticals to Enter Into Collaborat...

Some related posts from Technorati and Google.

[the technologeek] Nitto Denko and Quark Pharmaceuticals to Enter Into Collaboration ...: Nitto Denko Corporation, Japan’s leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases …

[The Haystack] RNAi Roundup #4 | The Haystack: Nitto, which has expertise in polymeric formulations, says it picked Quark because of the chemical modification it had made to the siRNA that have eliminated worries over an immune response from the therapeutic.

[Hormone Replacement Therapy News] Hormone Replacement Therapy News » Blog Archive » Nitto Denko ...: "Notwithstanding the provisions of section 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phono-records or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright.

[Silico Research] Nitto Denko and Quark Pharmaceuticals collaborate to develop siRNA ...: Nitto Denko and Quark Pharmaceuticals have announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases. The collaboration is designed to develop siRNA drugs using Quark’s RNAi technologies and novel structures and Nitto Denko’s drug delivery technologies.

[Life Sciences Blog] Reportlinker Adds Delivering RNAi-Based Therapeutics (and ...: (RXi Therapeutics) RNAi-Based Therapeutics in Other Therapeutic Areas Case study: ALN-TTR siRNA (Alnylam Pharmaceuticals) Case study: HSP47 siRNA (Nitto Denko Technical Corporation) Case study: QPI-1002 (Silence Therapeutics/Quark .

[microRNA Blog] Number of Companies working on RNAi Based Therapeutics is Exploding!: Mirna Therapeutics, MiRagen Therapeutics. Nitto Denko Technical Corp. Opko Health. Oxford BioMedica. Polyplus Transfection. Quark Pharmaceuticals. Regulus Therapeutics. RXi Therapeutics. Santaris Pharma. Senesco Technologies ...

Reflected tags on Technorati: Blog, Quark, Graphic Design Blog